Skip to content

Effect of Virechana Karma, Kostha-Shudhdhi and Matra-Basti in the treatment of Pakshaghata (Paralysis)

An open labelled randomized comparative clinical trial of Virechana Karma, Kostha-Shudhdhi and Matra-Basti in the management of Pakshaghata (Hemiplegia) - KARMA

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2020/06/025961
Enrollment
90
Registered
2020-06-18
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: I69- Sequelae of cerebrovascular disease

Interventions

Intervention1: Group A: Patients would undergo classical Virechana karma with Eranda taila 50-100 ml along with milk 50-100 ml followed by Matra-Basti with Bala taila 48 ml for 9 days (Sadharana Matra

Sponsors

Institute For Post Graduate Training And Research In Ayurveda
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients diagnosed as Pakshaghata (CVA with hemiplegia). Patients who are Yogya for Virechana karma and Sneha-Basti. Age group of 20-70 yrs. will be selected. Patient willing to participate in the trial.

Exclusion criteria

Exclusion criteria: Patients of Intracranial infection Degenerative lesions, Intracranial space occupying lesions and trauma. Patients with altered sensorium. Malignant and accelerated hypertension, Uncontrolled diabetes Patient undergoing regular treatment for any other sevear condition like Carcinoma, AIDS, Tuberculosis

Design outcomes

Primary

MeasureTime frame
Relief in signs and symptoms of Pakshaghata (Hemiplegia)Timepoint: 25 DAYS

Secondary

MeasureTime frame
Improvement in quality of life of patientTimepoint: 25 DAYS

Countries

India

Contacts

Public ContactProf Anup B Thakar

Institute of Post Graduate Teaching and Research in Ayurveda

anup_thakar@yahoo.com9427776660

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026